GENMAB A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,042 DKK | +0.62% |
|
-0.68% | -5.15% |
| Apr. 16 | Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug | MT |
| Apr. 16 | Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024 | CI |
Presenter SpeechDeirdre Connelly (Executives)Good afternoon, and welcome to Genmab's 2022 Annu...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
2,030
DKK
Average target price
2,434
DKK
Spread / Average Target
+19.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.15% | 18.79B | |
| +2.49% | 96.73B | |
| -0.32% | 21.31B | |
| -16.61% | 21.21B | |
| -42.14% | 16.37B | |
| -27.40% | 13.68B | |
| +1.44% | 13.44B | |
| +21.29% | 10.98B | |
| -21.79% | 8.56B | |
| +12.82% | 8.12B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Transcript : Genmab A/S - Shareholder/Analyst Call
